Whitehawk Therapeutics Inc (NASDAQ: WHWK)’s stock price has gone rise by 6.08 in comparison to its previous close of 1.48, however, the company has experienced a 3.97% increase in its stock price over the last five trading days. prnewswire.com reported 2025-03-26 that MORRISTOWN, N.J., March 26, 2025 /PRNewswire/ — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced the successful closing of the divestiture of Aadi Subsidiary, Inc. (“Aadi Sub”) to Kaken Pharmaceuticals (“Kaken”) for a cash payment of $100 million plus certain customary adjustments, completing the strategic transformation first announced in December 2024.
Is It Worth Investing in Whitehawk Therapeutics Inc (NASDAQ: WHWK) Right Now?
Moreover, the 36-month beta value for WHWK is 0.64. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for WHWK is 31.93M and currently, short sellers hold a 3.58% of that float. On May 01, 2025, WHWK’s average trading volume was 127.95K shares.
WHWK’s Market Performance
WHWK stock saw a decrease of 3.97% in the past week, with a monthly decline of -7.65% and a quarterly a decrease of -45.49%. The volatility ratio for the week is 6.41%, and the volatility levels for the last 30 days are 7.47% for Whitehawk Therapeutics Inc (WHWK). The simple moving average for the last 20 days is -0.41% for WHWK’s stock, with a simple moving average of -26.26% for the last 200 days.
Analysts’ Opinion of WHWK
Many brokerage firms have already submitted their reports for WHWK stocks, with Piper Sandler repeating the rating for WHWK by listing it as a “Neutral.” The predicted price for WHWK in the upcoming period, according to Piper Sandler is $1.75 based on the research report published on August 27, 2024 of the previous year 2024.
Jefferies gave a rating of “Hold” to WHWK, setting the target price at $1.50 in the report published on August 21st of the previous year.
WHWK Trading at -18.28% from the 50-Day Moving Average
After a stumble in the market that brought WHWK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.81% of loss for the given period.
Volatility was left at 7.47%, however, over the last 30 days, the volatility rate increased by 6.41%, as shares sank -8.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.99% lower at present.
During the last 5 trading sessions, WHWK rose by +2.65%, which changed the moving average for the period of 200-days by +4.03% in comparison to the 20-day moving average, which settled at $1.5755. In addition, Whitehawk Therapeutics Inc saw -50.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WHWK starting from BALL BRYAN, who sale 2,147 shares at the price of $2.35 back on Mar 03 ’25. After this action, BALL BRYAN now owns 102,853 shares of Whitehawk Therapeutics Inc, valued at $5,045 using the latest closing price.
Giacobello Scott M., the CHIEF FINANCIAL OFFICER of Whitehawk Therapeutics Inc, sale 2,806 shares at $2.35 during a trade that took place back on Mar 03 ’25, which means that Giacobello Scott M. is holding 23,944 shares at $6,594 based on the most recent closing price.
Stock Fundamentals for WHWK
Current profitability levels for the company are sitting at:
- -2.6 for the present operating margin
- -1.08 for the gross margin
The net margin for Whitehawk Therapeutics Inc stands at -2.45. The total capital return value is set at -1.27. Equity return is now at value -80.79, with -62.71 for asset returns.
Based on Whitehawk Therapeutics Inc (WHWK), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -71.49.
Currently, EBITDA for the company is -64.63 million with net debt to EBITDA at 0.43. When we switch over and look at the enterprise to sales, we see a ratio of 1.62. The receivables turnover for the company is 4.4for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.59.
Conclusion
To wrap up, the performance of Whitehawk Therapeutics Inc (WHWK) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
